In addition, a survey has been conducted for current registered clinical trials of CP therapy for COVID-19, including a description of their characteristics such as study design, patient populations, outcomes, eligibility criteria for CP donors, CP collection, antibody titer, and CP dose [218]. The gene discussed is CP; the disease is COVID-19.